Complications of Treatment for Symptomatic Vitreous Floaters: A Review

Kakulavarapu, Srividya; Kiryakoza, Lauren; Sridhar, Jayanth

doi:10.1097/iio.0000000000000433

Cited by 5 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a few patients reported that their floaters got worse after receiving Nd:YAG laser vitreolysis [ 23 ], this in vivo study found that the laser vitreolysis therapy did not result in the development of any new floaters. Nguyen et al [ 24 ] also reported that the vitreous echo density of Nd:YAG-treated eyes was 23% less than that of untreated eyes with vitreous floaters.…”

Section: Discussionmentioning

confidence: 83%

No side effects on rabbit retina or vitreous microenvironment by nd:YAG laser vitreolysis

Lin,

Zhang,

et al. 2024

BMC Ophthalmol

View full text Add to dashboard Cite

Background To explore the safety of Neodymium:Yttrium-aluminum-garnet (Nd:YAG) laser vitreolysis based on the histological examination of the retina and the alteration of vitreous cytokines in the rabbits. Methods Nine male New Zealand rabbits underwent Nd:YAG laser vitreolysis of 10 mJ x 500 pulses in the left eyes, while the right eyes were used as controls. Intraocular pressure, color fundus photography, and ultrasound B scan were measured before, as well as 1 day, 4 weeks, and 12 weeks after Nd:YAG laser vitreolysis. Three rabbits were euthanized 1 day, 4 weeks, and 12 weeks after treatment, respectively. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and hematoxylin-eosin (H&E) staining were used to look for pathological changes in the retina. An enzyme-linked immunosorbent assay (ELISA) was utilized to detect the expression of vascular endothelial growth factor (VEGF) and some inflammatory cytokines, including interferon inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1) and interlenkin 6 (IL-6) in the vitreous humor. The ascorbic acid (AsA) and total reactive antioxidant potential (TRAP) in the vitreous humor were also measured. Results Following Nd:YAG laser vitreolysis, the levels of VEGF, IP-10, MCP-1, IL6, AsA, and TRAP in the vitreous humor did not change substantially (P > 0.05). There were no detectable pathological changes in the retinal tissues, and no apoptotic signal was found. Conclusions Rabbits tolerate Nd:YAG laser vitreolysis without observable impact on retinal tissue or the microenvironment of the vitreous.

show abstract

Section: Discussionmentioning

confidence: 83%

No side effects on rabbit retina or vitreous microenvironment by nd:YAG laser vitreolysis

Lin,

Zhang,

et al. 2024

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…In 1993, Tsai et al [14] introduced YAG laser vitreolysis for treating oaters. Subsequently, Shah et al [4] were the rst to evaluate the safety and e cacy of this treatment in a randomized controlled trial.…”

Section: Discussionmentioning

confidence: 99%

No side effects on retina or vitreous microenvironment by YAG laser vitreolysis in vivo

Lin,

Zhang,

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: To explore the safety of yttrium-aluminum-garnet (YAG) laser vitreolysis based on the histological examination of the retina and the alteration of vitreous cytokines in vivo. Methods: Nine male New Zealand rabbits underwent YAG laser vitreolysis of 10 mJ x 500 pulses in the left eyes, while the right eyes were used as controls. Intraocular pressure, color fundus photography, and ultrasound B scan were measured before, as well as 1 day, 4 weeks, and 12 weeks after YAG laser vitreolysis. Three rabbits were euthanized 1 day, 4 weeks, and 12 weeks after treatment, respectively. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and hematoxylin-eosin (H&E) staining were used to look for pathological changes in the retina. An enzyme-linked immunosorbent assay (ELISA) was utilized to detect the expression of vascular endothelial growth factor (VEGF) and some inflammatory cytokines, including interferon inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1) and interlenkin 6 (IL-6) in the vitreous humor. The ascorbic acid (AsA) and total reactive antioxidant potential (TRAP) in the vitreous humor were also measured. Results: Following YAG laser vitreolysis, the levels of VEGF, IP-10, MCP-1, IL6, AsA, and TRAP in the vitreous humor did not change substantially (P > 0.05). There were no detectable pathological changes in the retinal tissues, and no apoptotic signal was found. Conclusions: YAG laser vitreolysis has no noticeable effects on retinal tissue or the microenvironment of the vitreous, so it is a safe procedure.

show abstract

“…With aging, adhesions between the posterior vitreous gel and the retina weaken, leading to a posterior vitreous detachment. This, in combination with liquefaction of the vitreous gel, can lead to clinically significant vitreous floaters [2,5]. Vitreous floaters may be symptomatic and characterized as dark spots or shadows in the vision.…”

Section: Introductionmentioning

confidence: 99%

Management of vitreous floaters: a review

Aleman,

Kiryakoza,

Sridhar

et al. 2024

Current Opinion in Ophthalmology

Self Cite

View full text Add to dashboard Cite

Purpose of review Vitreous floaters, characterized by the perception of spots or shadows in the visual field, commonly result from posterior vitreous detachment and can cause chronic symptoms in affected patients. The diagnosis of posterior vitreous detachment is typically determined clinically and can sometimes be confirmed with optical coherence topography (OCT) [1▪▪]. The objective of this review is to review management options for symptomatic vitreous floaters. Recent Findings Symptoms of vitreous floaters may be mild or may significantly affect patient quality of life. Observation is the most common management strategy. Procedural management options include pars plana vitrectomy (PPV) and neodymium-doped yttrium aluminium garnet (Nd:YAG) vitreolysis. PPV is considered the most definitive management option for vitreous floaters. PPV, however, carries inherent risks, notably infection, cataract formation, and retinal detachment [2]. Nd:YAG laser vitreolysis is a less invasive alternative with studies demonstrating varied success [1▪▪,3,4]. Summary This review provides insights into the current state of knowledge regarding the management of vitreous floaters and can guide clinical decision-making.

show abstract

Complications of Treatment for Symptomatic Vitreous Floaters: A Review

Abstract: Symptomatic floaters are those that affect daily life and decrease qualityof-life (QOL) for a duration of at least 3 months. 8 Patients typically complain

Cited by 5 publications

References 49 publications

No side effects on rabbit retina or vitreous microenvironment by nd:YAG laser vitreolysis

No side effects on rabbit retina or vitreous microenvironment by nd:YAG laser vitreolysis

No side effects on retina or vitreous microenvironment by YAG laser vitreolysis in vivo

Management of vitreous floaters: a review

Contact Info

Product

Resources

About